Martin Münzel

Martin Münzel

Auto-generated profile, based on publicly available information

Martin Münzel

Center for Integrated Protein Science, Department of Chemistry, Ludwig-Maximilians-University Munich, Butenandtstr. 5-13, 81377 Munich, Germany

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Cell
Verified
Journal Article
Closed access
CSCornelia G. Spruijt
Cornelia G. Spruijt
FGFelix Gnerlich
Felix Gnerlich
ASArne H. Smits
Arne H. Smits
TPToni Pfaffeneder
Toni Pfaffeneder
PJPascal W.T.C. Jansen
Pascal W.T.C. Jansen
MVMichiel Vermeulen
Michiel Vermeulen

23 December 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Daniel GlobischDaniel Globisch
Daniel Globisch
MMMartin Münzel
Martin Münzel
MMMarkus Müller
Markus Müller
Stylianos MichalakisStylianos Michalakis
Stylianos Michalakis
MWMirko Wagner
Mirko Wagner
TCThomas Carell
Thomas Carell
5–Hydroxymethylcytosine (hmC) was recently detected as the sixth base in mammalian tissue at so far controversial levels. The function of the modified base is currently unknown, but it is certain that the base is generated from 5-methylcytosine (mC). This fuels the hypothesis that it represents an intermediate of an active demethylation process, which could involve further oxidation of the hydroxymethyl group to a formyl or carboxyl group followed by either deformylation or decarboxylation. Here, we use an ultra-sensitive and accurate isotope based LC-MS method to precisely determine the levels of hmC in various mouse tissues and we searched for 5–formylcytosine (fC), 5-carboxylcytosine (caC), and 5–hydroxymethyluracil (hmU) as putative active demethylation intermediates. Our data suggest that an active oxidative mC demethylation pathway is unlikely to occur. Additionally, we show using HPLC-MS analysis and immunohistochemistry that hmC is present in all tissues and cell types with highest concentrations in neuronal cells of the CNS.

30 June 2011 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
TPToni Pfaffeneder
Toni Pfaffeneder
BHBenjamin Hackner
Benjamin Hackner
MTMatthias Truß
Matthias Truß
MMMartin Münzel
Martin Münzel
MMMarkus Müller
Markus Müller
TCThomas Carell
Thomas Carell

16 July 2010 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
MMMartin Münzel
Martin Münzel
Daniel GlobischDaniel Globisch
Daniel Globisch
TBTobias Brückl
Tobias Brückl
MWMirko Wagner
Mirko Wagner
VWVeronika Welzmiller
Veronika Welzmiller
TCThomas Carell
Thomas Carell

17 June 2011 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
MMMartin Münzel
Martin Münzel
Daniel GlobischDaniel Globisch
Daniel Globisch
TCThomas Carell
Thomas Carell

6 April 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAkane Kawamura
Akane Kawamura
MMMartin Münzel
Martin Münzel
TKTatsuya Kojima
Tatsuya Kojima
CYClarence Yapp
Clarence Yapp
BBBhaskar Bhushan
Bhaskar Bhushan
CSChristopher J. Schofield
Christopher J. Schofield
The JmjC histone demethylases (KDMs) are linked to tumour cell proliferation and are current cancer targets; however, very few highly selective inhibitors for these are available. Here we report cyclic peptide inhibitors of the KDM4A-C with selectivity over other KDMs/2OG oxygenases, including closely related KDM4D/E isoforms. Crystal structures and biochemical analyses of one of the inhibitors (CP2) with KDM4A reveals that CP2 binds differently to, but competes with, histone substrates in the active site. Substitution of the active site binding arginine of CP2 to N-ɛ-trimethyl-lysine or methylated arginine results in cyclic peptide substrates, indicating that KDM4s may act on non-histone substrates. Targeted modifications to CP2 based on crystallographic and mass spectrometry analyses results in variants with greater proteolytic robustness. Peptide dosing in cells manifests KDM4A target stabilization. Although further development is required to optimize cellular activity, the results reveal the feasibility of highly selective non-metal chelating, substrate-competitive inhibitors of the JmjC KDMs.